

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8351754

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PIL HO KIM	11/27/2023
SUNG YUN CHO	11/27/2023
JAE DU HA	11/27/2023
CHI HOON PARK	11/23/2023
JONG YEON HWANG	11/27/2023
HYUN JIN KIM	11/27/2023
SONG HEE LEE	11/27/2023
YE SEUL LIM	11/27/2023
HAN WOOL KIM	11/27/2023
SUN MI YOO	11/27/2023
BEOM SEON SUH	11/27/2023
JI YOUN PARK	11/27/2023
JE HO RYU	11/27/2023
JUNG MIN AHN	11/27/2023
HEE JUNG MOON	11/27/2023
HO HYUN LEE	11/27/2023
RECEIVING PARTY DATA	
Name:	KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Street Address:	141, GAJEONG-RO, YUSEONG-GU
City:	DAEJEON
State/Country:	KOREA, REPUBLIC OF
Postal Code:	34114
Name:	UBIX THERAPEUTICS, INC.
Street Address:	C-1401, 7, BEOBWON-RO 11-GIL, SONGPA-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	05836
PROPERTY NUMBERS Total: 1	

Property Type	Number
Application Number:	18573904

CORRESPONDENCE DATA

Fax Number: (202)783-6031

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2027836040

Email: mshirai@rfem.com, KNogami@rothwellfigg.com

Correspondent Name: ROTHWELL, FIGG, ERNST & MANBECK, P.C.

Address Line 1: 901 NEW YORK AVENUE, N.W.

Address Line 2: SUITE 900 EAST

Address Line 4: WASHINGTON, D.C. 20001

ATTORNEY DOCKET NUMBER:	3738-205
NAME OF SUBMITTER:	MIHOKO SHIRAI
SIGNATURE:	/MIHOKO SHIRAI/
DATE SIGNED:	12/27/2023

Total Attachments: 3

source=3738-205 Assignment#page1.tif

source=3738-205 Assignment#page2.tif

source=3738-205 Assignment#page3.tif

ASSIGNMENT BY INVENTOR(S) OF PATENT APPLICATION FOR ALL COUNTRIES

BE IT KNOWN THAT, for good and valuable consideration paid to the undersigned inventor(s) (hereinafter ASSIGNOR(S)) by

Name: **KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY**

Address: 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 Republic of Korea

Name: **UBIX THERAPEUTICS, INC.**

Address: C-1401, 7, Beobwon-ro 11-gil, Songpa-gu, Seoul 05836 Republic of Korea

(hereinafter ASSIGNEE),

the receipt and adequacy of which are hereby acknowledged, ASSIGNOR(s) hereby sell(s), assign(s) and transfer(s) to ASSIGNEE

all of his/her right, title and interest in, to and under the invention and application entitled:

**NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION
FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF**

for which application for Letters Patent of the United States ASSIGNOR(S) is/are the sole or a joint inventor and which application was executed on even date herewith or is identified as follows

U.S. Serial No. or PCT Appln. No.: PCT/KR2022/009087 Filing Date: June 24, 2022
(Rothwell, Figg, Ernst & Manbeck is hereby authorized to insert the series code, serial or application number and/or filing date hereon, when known)
and all Letters Patent of the United States to be obtained on said application or on any continuation (including any continuation-in-part), division, reissue, reexamination or extension thereof and all rights connected therewith, and all applications for Letters Patent which may hereafter be filed for said invention, or improvement thereof, in any country or countries foreign to the United States, and all Letters Patent which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof and all rights of priority in any such country or countries based upon the filing of the said application for Letters Patent of the United States which are created by any law, treaty or international convention, for the full term or terms for which the same may be granted, including all rights to recover damages for any and all past infringement; and


ASSIGNOR(S) agree(s) to execute all papers necessary in connection with said application and any continuing, divisional, reissue or reexamination applications thereof and to execute separate assignments in connection with such applications as ASSIGNEE may deem necessary.


ASSIGNOR(S) agree(s) to execute all papers necessary in connection with any interference, litigation, or other legal proceeding which may be declared concerning this application or any continuation, division, reissue or reexamination thereof or Letters Patent, reissue patent or reexamination certificate issued thereon and to cooperate with ASSIGNEE in every way possible in obtaining and producing evidence and proceeding with such interference, litigation, or other legal proceeding.


ASSIGNOR(S) covenant(s) that he/she has the full right to convey the entire interest herein assigned and has not executed, and will not execute, any agreement in conflict herewith.


ASSIGNOR(S) acknowledge(s) that ASSIGNEE may appoint any attorney or practitioner of ASSIGNEE'S choice to prosecute any application or other legal proceeding involving said invention and ASSIGNOR(S) further acknowledge(s) that any attorney or practitioner so appointed by ASSIGNEE does not represent ASSIGNOR(S) and that such appointment by ASSIGNEE does not create any attorney-client relationship between ASSIGNOR(S) and any attorney or practitioner appointed by ASSIGNEE.


IN WITNESS WHEREOF, ASSIGNOR(S) has/ have affixed his/her signature below.


Signature: 	Date: Nov. 27, 2023
Typed Name: KIM, Pil Ho	


Signature: 	Date: Nov. 27, 2023
Typed Name: CHO, Sung Yun	


Signature: 	Date: Nov. 27, 2023
Typed Name: HA, Jae Du	


Signature: 	Date: Nov. 23, 2023
Typed Name: PARK, Chi Hoon	


Signature: 	Date: Nov. 27, 2023
Typed Name: HWANG, Jong Yeon	


Signature: 	Date: Nov. 27, 2023
Typed Name: KIM, Hyun Jin	


Signature: 	Date: Nov. 27, 2023
Typed Name: LEE, Song Hee	


Signature: 	Date: Nov. 27, 2023
Typed Name: LIM, Ye Seul	


Signature: 	Date: Nov. 27, 2023
Typed Name: KIM, Han Wool	


Signature: 	Date: Nov. 27, 2023
Typed Name: YOO, Sun Mi	


Signature: 
Typed Name: SUH, Beom Seon
Date: Nov. 27, 2023


Signature: 
Typed Name: PARK, Ji Youn
Date: Nov. 27, 2023


Signature: 
Typed Name: RYU, Je Ho
Date: Nov. 27, 2023

Signature: 
Typed Name: AHN, Jung Min
Date: Nov. 27, 2023

Signature: 
Typed Name: MOON, Hee Jung
Date: Nov. 27, 2023

Signature: 
Typed Name: LEE, Ho Hyun
Date: Nov. 27, 2023

ACCEPTED AND ACKNOWLEDGED FOR AND ON BEHALF OF THE ASSIGNEE:
ASSIGNEE NAME: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
SIGNATURE OF AUTHORIZED PERSON 
TYPED/PRINTED NAME OF AUTHORIZED PERSON LEE YOUNG SEOK
TYPED TITLE Head of Office of Technology Commercialization
DATE: 30 November 2023

ACCEPTED AND ACKNOWLEDGED FOR AND ON BEHALF OF THE ASSIGNEE:
ASSIGNEE NAME: UBIX THERAPEUTICS, INC.
SIGNATURE OF AUTHORIZED PERSON 
TYPED/PRINTED NAME OF AUTHORIZED PERSON BOKWANG SEO
TYPED TITLE: CEO, UbiX Therapeutics, Inc.
DATE: 30, November 2023

NO LEGALIZATION REQUIRED. THIS DOCUMENT MAY BE NOTARIZED IF DESIRED FOR FURTHER PROOF OF EXECUTION.